

Figure 1




Fig. 2 A




Fig. 2 B




Fig. 2C




Fig. 3A




Fig. 3B




Fig. 4




Fig. 5




Fig. 6




Fig. 7






Fig. 8A



009280-50928000

Fig. 8B



[illegible]

Western Blotting of anti-CD3 Diavalent DT390-scAb

1 2 3 4 M

— 250 KD

— 148 KD

96 KD —

— 60 KD

— 42 KD

1, 2. non-reduced condition.
2, 4. reduced condition
1, 3 and 2, 4 are two samples

Fig. 10





Fig. 11





cDNA of UCHT1 hybridoma
5' ————— 3'

PCR





pBlue-huIgM
Plasmid




Recombinant amplification



Clone into pBK/CMV



Ligation into pET 17b




[illegible]

Fig. 13






Fig. 14




[illegible]

Generating the conjugates of DTMI with UCHT1

Fig. 16

1. Full-length DTMI-scUCHT1



3 483 DTMI-scUCHT1





Fig. 17




Fig. 19A




Fig. 19B





Fig. 20

Serum IL-12 levels after CD3-IT treatment



Serum IFN- γ levels after CD3-IT treatment

Fig. 21






Fig. 22



009000 509000 60

Fig. 23



DAYS AFTER CD-3 IT